Background. Gastrointestinal (GI) cancer, including gastric cancer (GC), colorectal cancer (CRC), and esophageal squamous cell carcinoma (ESCC), is the most common malignancy worldwide. To identify genes that encode transmembrane proteins present in GI cancer, Escherichia coli ampicillin secretion trap libraries were generated from MKN-74 GC cells, and BST2 was identified as overexpressed in GC. This study analyzed the expression and function of the BST2 gene in human GI cancers and examined the relationship between bone marrow stromal antigen-2 (BST-2) expression and GI patient clinicopathologic characteristics. Methods. Expression and distribution of BST-2 protein was analyzed by immunohistochemistry in 180 GC cases, 140 CRC cases, and 132 ESCC cases. Cell growth was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results. Immunohistochemical analysis of BST-2 in GC tissues showed that 65 (36 %) of 180 GC cases were positive for BST-2. Uni-and multivariate analyses demonstrated that BST-2 expression is an independent prognostic classifier of GC patients. Immunohistochemical analysis showed that 46 % of 140 CRC cases and 27 % of 132 ESCC cases were positive for BST-2. In ESCC, BST-2 expression was an independent prognostic predictor for survival. The growth of BST2 small interfering RNA (siRNA)-transfected GC cells was significantly slower than the growth of negative control siRNA-transfected GC cells. The levels of phosphorylated epidermal growth factor receptor, extracellular signal-regulated kinase, and Akt were lower in BST2 siRNA-transfected GC cells than in control cells. Conclusions. The results suggest that BST-2 is involved in tumor progression and serves as an independent prognostic classifier for patients with GC. Because BST-2 is expressed on the cell membrane, BST-2 could be a therapeutic target for GC, CRC, and ESCC.
available for CRC, 4 no molecular-targeted drug exists for ESCC. Therefore, the development of novel therapeutic targets is required for better treatment of GI cancer.
Escherichia coli ampicillin secretion trap (CAST) is a signal sequence trap method for identifying genes that encode transmembrane or secretory proteins. 5 We previously performed CAST using GC cell lines 6, 7 and GC tissue samples 8, 9 and identified several genes that encode transmembrane proteins present in GC cells, including bone marrow stromal antigen 2, which was overexpressed in GC.
Bone marrow stromal antigen 2 (BST2) encodes BST-2 protein, also known as HM1.24 or CD317. A lipid raftassociated type 2 transmembrane glycoprotein, BST-2 is 10 overexpressed in multiple myeloma cells. 11 A previous study reported that immunotherapy with a monoclonal antibody against BST-2 reduced tumor size and improved survival in a multiple myeloma model in mice. 12 A monoclonal antibody against BST-2 can induce antibodydependent cellular cytotoxicity and complement-dependent cytotoxicity, suggesting that monoclonal antibody against BST-2 may be effective for a wide range of human malignancies. In fact, high levels of BST-2 have been reported in ovarian cancer, 13 neoplastic B cells, 11 breast cancer, 14 endometrial cancer, 15 and lung cancer. 16 However, expression of BST-2 in CRC and ESCC has not been investigated.
The current study analyzed the expression and function of BST-2 in human GI cancers and examined the relationship between BST-2 expression and the clinicopathologic characteristics of GI patients.
MATERIALS AND METHODS

Cell Lines
This study examined three cell lines derived from human GC (MKN-1, MKN-45, and MKN-74), two cell lines derived from human CRC (Lovo and WiDr), and six cell lines derived from human esophageal cancer (TE-1, TE-5, TE-8, TE-9, TE-10, and TE-11). All the cell lines were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). The cell lines all were maintained in RPMI 1640 (Nissui Pharmaceutical Co, Ltd, Tokyo, Japan) containing 10 % fetal bovine serum (BioWhittaker, Walkersville, MD, USA) in a humidified atmosphere of 5 % carbon dioxide (CO 2 ) and 95 % air at 37°C.
CAST Library Construction
In this study, CAST library construction was performed as described previously. 5 
Tissue Samples
A total of 472 primary tumor samples were collected. The patients were treated at the Hiroshima University Hospital or an affiliated hospital. All the patients underwent curative resection. Only the patients without preoperative radio-or chemotherapy were enrolled in the study.
For quantitative reverse transcription-polymerase chain reaction (qRT-PCR), 20 GC samples and corresponding non-neoplastic mucosa samples were used. The samples were frozen immediately in liquid nitrogen and stored at -80°C until use. For immunohistochemical analysis, we used archival formalin-fixed, paraffin-embedded tissues from 452 patients who had undergone surgical excision for GC (n = 180), CRC (n = 140), or ESCC (n = 132).
Tumor staging was determined according to the tumornode-metastasis (TNM) classification system. 17 Histologic classification of GC was determined according to the Lauren classification system. 18 Histologic classifications of CRC and ESCC were based on the World Health Organization system.
Information on the administration of postoperative chemotherapy was available for all the patients with GC, CRC, or ESCC. Postoperative chemotherapy regimens were primarily 5-fluorouracil-based regimens. This study was approved by the Ethical Committee for Human Genome Research of Hiroshima University (Hiroshima, Japan).
Immunohistochemistry
Immunohistochemical analysis was performed with a Dako Envison ? Rabbit Peroxidase Detection System (Dako Cytomation, Carpinteria, CA, USA) as described previously. 19 For the primary antibody, we used a rabbit polyclonal anti-BST-2 antibody (Sigma-Aldrich, MO, USA). A result was considered positive if at least 10 % of the cancer cells were stained. When fewer than 10 % of cancer cells were stained, the immunostaining was considered negative.
Statistical Analysis
For the statistical analyses, SPSS software (SPSS Inc., Chicago, IL, USA) was used. A p value lower than 0.05 was considered statistically significant.
Western Blot, qRT-PCR, RNA Interference (RNAi), Expression Vector, Cell Growth Assay, and In Vitro Invasion Assay
These methods are described in detail in the Supplementary Material.
RESULTS
Generation of the MKN-74 CAST Library
To identify genes encoding transmembrane proteins in GC, we generated a CAST library from the GC cell line MKN-74 and sequenced 1152 ampicillin-resistant colonies. To identify genes aberrantly expressed in GC, we compared the gene list from the MKN-74 GC cell line CAST library with the normal stomach CAST library. The normal stomach CAST data were described previously. 6 Genes detected at least three times in the MKN-74 CAST library but not detected in the normal stomach CAST library were selected. A total of 16 candidates from MKN-74 cells were obtained ( Table 1) .
The gene showing the highest expression in MKN-74 cells was TM9SF3. We previously found that TM9SF3 is one of the upregulated genes in GC using the CAST method and reported that expression of transmembrane 9 superfamily member 3 protein is frequently detected in scirrhous type GC. 8 The gene showing the second highest expression was CLDN7, and overexpression of CLDN7 in GC has been reported previously. 20 The gene with the third highest expression was BST2. We previously reported overexpression of BST2 in GC, 6 but detailed expression analysis of BST2 had not been analyzed. Therefore, we selected BST2 for further examination.
Expression of BST2 mRNA was analyzed by qRT-PCR in 20 GC tissue samples and corresponding non-neoplastic mucosa samples. We calculated the ratio of target gene mRNA expression levels between GC tissue (T) and corresponding non-neoplastic mucosa (N), considering that T/ N ratios greater than twofold represented overexpression. The qRT-PCR results demonstrated overexpression of BST2 mRNA in seven GC cases (35 %).
Immunohistochemical Analysis of BST-2 in GC
Because our study aimed to identify genes that encode transmembrane proteins, we next examined the location of BST-2 protein in GC cells. The anti-BST-2 antibody detected a single band of approximately 36 kDa in Western blots of cell extracts from MKN-74 GC cells, confirming the specificity of the antibody (Fig. 1a) .
Next, immunohistochemistry was performed on 180 GC tissue samples. In non-neoplastic gastric mucosa, weak or no staining of BST-2 was observed in the foveolar epithelium or stromal cells, whereas GC tissue showed stronger, more extensive staining (Fig. 1b) . Expression of BST-2 was frequently observed in intestinal type GC (Fig. 1c) . Some GC cells of diffuse type GC also were stained by BST-2 ( Fig. 1d) . Staining of BST-2 was observed mainly on GC cell membrane. Many GC cases showed heterogeneity of BST-2 staining, and the percentage of BST-2-stained GC cells ranged from 0 to 70 %. A tendency for upregulation of BST-2 at the invasive front was not observed. In total, 65 (36 %) of 180 GC cases were positive for BST-2. We next examined the relationship of BST-2 staining to clinicopathologic characteristics (Table 2) . GC cases positive for BST-2 were found more frequently in stages 2, 3, and 4 cases than in stage 1 cases.
Kaplan-Meier analysis showed poorer survival in BST-2-positive GC cases than in BST-2-negative GC cases (p = 0.0174; Fig. 1d ). Uni-and multivariate Cox proportional hazards analyses showed that BST-2 expression was an independent prognostic predictor for the survival of patients with GC (Table 3) .
Expression and Distribution of BST-2 in CRC
Expression of BST-2 in CRC had not been investigated previously. We next performed immunohistochemistry on 140 CRC tissue samples. In non-neoplastic colonic mucosa, weak or no staining of BST-2 was observed. In contrast, CRC tissue showed stronger, more extensive staining than corresponding non-neoplastic mucosa (Supplemental Fig. 1a) . Staining of BST-2 was observed mainly on CRC cell membrane (Supplemental Fig. 1b) . In total, 64 (46 %) of 140 CRC cases were positive for BST-2.
We also examined the relationship of BST-2 staining to clinicopathologic characteristics (Supplemental Table 1 ). Our findings showed CRC cases positive for BST-2 more frequently in stages 2, 3, and 4 cases than in stage 1 cases.
Kaplan-Meier analysis showed poorer survival in BST-2-positive CRC cases than in BST-2-negative CRC cases (p = 0.0268; Supplemental 
2 expression was not an independent prognostic predictor for the survival of patients with CRC (Supplemental Table 2 ).
Expression and Distribution of BST-2 in ESCC
Because expression of BST-2 in ESCC had not been evaluated, the expression and distribution of BST-2 protein was examined by immunohistochemistry on 132 ESCC tissue samples. In non-neoplastic esophageal mucosa, weak or no staining of BST-2 was observed. In contrast, ESCC tissue showed stronger, more extensive staining than corresponding non-neoplastic mucosa (Supplemental Fig. 1d) . Staining of BST-2 was observed mainly on ESCC cell membrane (Supplemental Fig. 1e ). In total, 36 (27 %) of 132 ESCC cases were positive for BST-2.
We investigated the relationship of BST-2 staining to clinicopathologic characteristics (Supplemental Table 3 ). The ESCC cases positive for BST-2 were found more frequently in lymphatic invasion-positive cases than in lymphatic invasion-negative cases.
Kaplan-Meier analysis showed poorer survival in BST-2-positive ESCC cases than in BST-2-negative ESCC cases (p = 0.0246; Supplemental Fig. 1f) . Uni-and multivariate Cox proportional hazards analyses showed that BST-2 expression was an independent prognostic predictor for the survival of patients with ESCC (Supplemental Table 4 ). 
Effect of BST2 on Cell Growth and Invasiveness
The biologic function of BST-2 in GC had not been investigated. Thus, we next examined the effect of BST2 inhibition using three different small interfering RNA (siRNA) sequences on cell growth activity and invasiveness. For these experiments, MKN-74 GC cells, which express detectable levels of BST-2 protein, were selected (Fig. 2a) . The expression of BST-2 was substantially suppressed by treatment with siRNA2 and siRNA3 using Western blot (Fig. 2b) . As shown by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, BST2 siRNA2-transfected and BST2 siRNA3-transfected MKN-74 cells had significantly less cell growth than negative control siRNA-transfected MKN-74 cells (Fig. 2c) . However, the invasiveness of BST2 siRNA2-transfected and BST2 siRNA3-transfected MKN-74 cells did not differ significantly from that of control cells, as shown by a modified Boyden chamber assay (data not shown). Because epidermal growth factor receptor (EGFR) can activate the Ras-Mek-Erk and the Akt-PI3 k pathways, leading to cancer cell proliferation and survival, 21 the effect of BST2 inhibition on EGFR signaling was analyzed. The levels of phosphorylated EGFR, extracellular signalregulated kinase (Erk), and Akt were lower in BST2 siRNA2-transfected and BST2 siRNA3-transfected MKN-74 cells than in control cells (Fig. 2b) . Similar results were observed in MKN-1 GC cells (Supplemental Fig. 2a, b) . The effect of BST2 inhibition on cell growth activity and invasiveness in CRC and ESCC cells also was investigated. The expression of BST-2 was substantially suppressed by transfection with BST2 siRNA2 and siRNA3 in the Lovo CRC cell line (Supplemental Fig. 2c ). As shown by MTT assay, BST2 siRNA2-transfected and BST2 siRNA3-transfected Lovo cells had significantly less cell growth than negative control siRNA-transfected Lovo cells (Supplemental Fig. 2d) . However, the invasiveness of BST2 siRNA2-transfected and BST2 siRNA3-transfected Lovo cells did not differ significantly from that of control cells, as shown by the modified Boyden chamber assay (data not shown).
Western blot analysis showed detectable BST-2 protein levels in TE-1 and TE-8 ESCC cell lines (Fig. 2d) . The expression of BST-2 was substantially suppressed by transfection with BST2 siRNA2 and siRNA3 in TE-8 cells (Fig. 2e) . As shown by MTT assay, BST2 siRNA2-transfected and BST2 siRNA3-transfected TE-8 cells had significantly less cell growth than negative control siRNAtransfected TE-8 cells (Fig. 2f) . However, the invasiveness of BST2 siRNA2-transfected and BST2 siRNA3-transfected TE-8 cells did not differ significantly from that of control cells, as shown by the modified Boyden chamber assay (data not shown). Similar results were observed in TE-1 cells (Supplemental Fig. 2e, f) .
To investigate the biologic significance of BST-2, the WiDr CRC cell line was transfected with vector-expressing BST-2. WiDr cells were selected because they express low levels of BST-2 (data not shown). Overexpression of BST-2 in BST-2-transfected WiDr cells was confirmed by Western blot (Supplemental Fig. 3a) . As shown by MTT assay, BST-2-transfected WiDr cells had significantly greater cell growth than empty vector-transfected WiDr cells (Supplemental Fig. 3b) .
DISCUSSION
In the current study, we generated CAST libraries from the MKN-74 GC cell line and identified 16 genes that encode transmembrane proteins. Among the upregulated genes, we focused on BST2 and examined expression of BST-2 protein in GC, CRC, and ESCC tissue samples. Immunohistochemical analysis demonstrated that 36 % of GC cases were positive for BST-2. Expression of BST-2 was associated with tumor stage and served as an independent prognostic classifier of patients with GC. These results suggest that BST-2 is involved in tumor progression and that BST-2 immunostaining is a clinically useful method for the prediction of GC patient survival.
In addition to GC, overexpression of BST-2 was observed in both CRC and ESCC. Immunohistochemical analysis demonstrated that 46 % of 140 CRC cases and 27 % of 132 ESCC cases were positive for BST-2. In CRC, BST-2 expression was associated with tumor stage and poor prognosis, as shown by Kaplan-Meier analysis. In contrast, BST-2 expression was not an independent prognostic classifier of patients with CRC, as shown by multivariate Cox proportional hazards analysis. In ESCC, BST-2 expression was associated with tumor stage and poor prognosis by Kaplan-Meier analysis. Furthermore, BST-2 expression was an independent prognostic classifier of patients with ESCC, as shown by multivariate Cox proportional hazards analysis. Taken together, these results suggest that BST-2 participates in malignant behavior of cancer cells.
The ability of cancer cell populations to expand in number is determined not only by the rate of cell proliferation, but also by the rate of apoptosis. In breast cancer cells, forced expression of BST-2 can increase cell proliferation activity and apoptosis evasion.
14,22 Expression of BST-2 is upregulated in tamoxifen-resistant breast cancer cells. 23 In multiple myeloma cells, anti-BST-2 antibody induces apoptosis. 24 These results indicate that BST-2 functions to inhibit apoptosis.
In the current study, BST2 siRNA-transfected GC cells showed significantly less cell growth than negative control siRNA-transfected GC cells. Similar results were observed in the CRC and ESCC cell lines. As shown by MTT assay, BST-2-transfected WiDr cells had significantly more cell growth than empty vector-transfected WiDr cells. Although the underlying mechanisms remain unclear, we showed that the levels of phosphorylated EGFR, Erk, and Akt were lower in BST2 siRNA-transfected GC cells than in control cells. A previous study showed that phosphorylation of Erk and Akt results in inhibition of apoptosis. 25 Thus, apoptosis also could be inhibited in BST2 siRNAtransfected GC cells. Taken together, these results demonstrate that BST-2 participates in activation of EGFR and suggest that EGFR signaling is important for GC cell growth in BST-2-positive cases.
The safety and efficacy of humanized anti-BST-2 antibody were investigated in a phase 1 and 2 clinical study of patients with relapsed or refractory multiple myeloma. 26 Although adverse events were modest and manageable, the response rate was low. This was considered to be due to the diminished activity of effector cells in this heavily pretreated patient population.
The current study demonstrated that 36 % of GC cases, 46 % of CRC cases, and 27 % of ESCC cases were positive for BST-2. Furthermore, BST2 siRNA-transfected GC cells showed significantly less cell growth than negative control siRNA-transfected GC cells. Therefore, humanized anti-BST-2 antibody can be effective for patients with BST-2-positive GC, CRC, or ESCC.
In summary, the current study yielded a list of genes that encode transmembrane proteins present in GC. The findings showed that BST-2 is overexpressed in GC, CRC, and ESCC and that BST-2 expression is an independent prognostic classifier of patients with GC. Overexpression of HER2 was detected in only 12 % patients with GC. 2 Because expression of BST-2 was found in 35 % of HER2-negative GC cases, BST-2 could be a useful therapeutic target for GC.
